Beam Therapeutics Inc. Research and Development in Process
Beam Therapeutics Inc. (BEAM) reported Research and Development in Process of $154.95 million for the 12-month period ending 2021-12-31, per its 10-K filed 2023-02-28.
Discontinued › Operating Expenses
us-gaap:ResearchAndDevelopmentInProcess · last filed 2023-02-28
- Beam Therapeutics Inc. research and development in process for the quarter ending 2021-12-31 was $0.00.
- Beam Therapeutics Inc. research and development in process for the quarter ending 2021-09-30 was $0.00.
- Beam Therapeutics Inc. research and development in process for the quarter ending 2021-06-30 was $0.00.
- Beam Therapeutics Inc. research and development in process for the quarter ending 2021-03-31 was $154.95M.
- Beam Therapeutics Inc. research and development in process for fiscal 2021 was $154.95M.
| Period end | Research and Development in Process 3 month | Research and Development in Process 6 month | Research and Development in Process 9 month | Research and Development in Process 12 month |
|---|---|---|---|---|
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $0.00 derived: sum of 2 quarters · filed 2023-02-28 | $0.00 derived: sum of 3 quarters · filed 2023-02-28 | $154.95M 10-K · filed 2023-02-28 |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-07 | $0.00 derived: sum of 2 quarters · filed 2022-11-07 | $154.95M 10-Q · filed 2022-11-07 | |
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $154.95M 10-Q · filed 2022-08-09 | ||
| 2021-03-31 | $154.95M 10-Q · filed 2022-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |